明胶海绵对 DEB-TACE 治疗不可切除的大肝细胞癌伴门静脉癌栓

StephenW

明胶海绵对 DEB-TACE 治疗不可切除的大肝细胞癌伴门静脉癌栓疗效和预后因素的评估：一项多中心回顾性研究
赵广生
, 宋刘
, 刘英
, 创力
, 王若玉
, 卞洁
， 显示所有
2021 年 12 月 10 日收到，2022 年 6 月 15 日接受，在线发布的接受作者版本：2022 年 6 月 16 日

    下载引文 https://doi.org/10.1080/17474124.2022.2091545 CrossMark Logo CrossMark

接受的作者版本
抽象的
客观的

探讨明胶海绵用于药物洗脱珠（DEB）经动脉化疗栓塞（GMD-TACE）治疗不可切除的大肝癌（HCC）和门静脉癌栓（PVTT）的临床疗效和预后因素。
方法

使用 mRECIST 标准进行回顾性分析，以评估 GMD-TACE 后的肿瘤反应。记录第一次干预后的总生存时间、中位生存时间、进展时间（TTP）和其他治疗方法。
结果

随访时间为2-110个月（平均17.97+19.12个月），中位随访时间为12.5个月，第一次GMD-TACE后的第一次TTP为4个月（95% CI 3.020-4.980）。中位总生存期 (OS) 时间为 14 个月 (95% CI 9.801-18.199)。 1 年、3 年和 5 年生存率分别为 53.6%、32.3% 和 8.9%。多因素分析显示，瘤栓类型是影响预后的独立因素，联合治疗是影响预后的保护因素。
结论

GMD-TACE 可作为无法切除的大型 HCC 联合 PVTT 的核心治疗。这可以提高生活质量，进一步提高中位OS，值得临床推广应用。

StephenW

Assessment of efficacy and prognostic factors by Gelfoam for DEB-TACE in unresectable large hepatocellular carcinoma with portal vein tumor thrombus: a multi-center retrospective study
Guang Sheng Zhao
, Song Liu
, Ying Liu
, Chuang Li
, Ruo Yu Wang
, Jie Bian
, show all
Received 10 Dec 2021, Accepted 15 Jun 2022, Accepted author version posted online: 16 Jun 2022

    Download citation https://doi.org/10.1080/17474124.2022.2091545 CrossMark Logo CrossMark

Accepted author version
Abstract
Objective

To explore the clinical efficacy and prognostic factors of the use of Gelfoam for drug-eluting bead (DEB) transarterial chemoembolization (GMD-TACE) in patients with unresectable large hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT).
Methods

A retrospective analysis was conducted using the mRECIST standard to evaluate tumor response after GMD-TACE. Overall survival time, median survival time, time to progression (TTP) after the first intervention, and other treatment methods were recorded.
Results

The follow-up time was 2–110 months (mean 17.97+19.12 months), the median follow-up time was 12.5 months, and the first TTP after the first GMD-TACE was 4 months (95% CI 3.020-4.980). The median overall survival (OS) time was 14 months (95% CI 9.801-18.199). The 1-, 3-, and 5-year survival rates were 53.6%, 32.3%, and 8.9%, respectively. Multivariate analysis showed that the type of tumor thrombus was an independent factors affecting prognosis, and combination therapy was a protective factor affecting prognosis.
Conclusions

GMD-TACE can be used as the core treatment for unresectable large HCC combined with a PVTT. This can improve the quality of life and further improve the median OS, and is worthy of clinical promotion and application.